Lead advisors Dr. Axel Hoos, GSK, Dr. Patrick Hwu, MD Anderson, and Dr. Ian McCaffery, Corvus Pharmaceuticals, present the 2nd annual Rational Combinations 360° program addressing business aspects, clinical advancements, and scientific data in IO combination strategies to fight a wider range of cancers.
Use code CRI20 to receive a 20% discount on registration!
Understanding and determining how to apply certain IO combinations for the right patients and specific tumor types is arguably the most difficult challenge within cancer immunotherapy.
Rational Combinations 360° provides the most up-to-date research, data, and progress on combination developments to help IO stakeholders:
- Be at the forefront of the most relevant research and developments for IO combinations from key leadership who are at the pulse of cancer immunotherapy
- Better understand assets that are available for potential combination to be able to give patients more treatment options
- Create and prioritize combination strategies targeted toward specific tumor types
- Foster collaboration amongst others working in all aspects of cancer immunotherapy by rounding up all stakeholders under one roof
The Rational Combinations 360° event concentrates on the following key areas:
- Derisking of Combination Immunotherapies
- Clinical Combination Immunotherapies
- Immuno Resistance – Drivers for Combination Therapy
- Novel Technologies and Emerging Biomarkers
- Clinical Manifestations of Immunological Toxicities
- Business Aspects for Combination Immunotherapy